Lamivudina Normon (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics natural nucleosides. When HIV reverse transcriptase incorporates lamivudine triphosphate into viral DNA, it terminates the DNA chain, preventing further viral replication and limiting disease progression.

The specific dose of Lamivudina Normon is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. Healthcare professionals set the appropriate regimen and adjust it as needed during treatment.

Safety data for lamivudine during pregnancy and lactation are limited. Prescribers weigh potential benefits against risks and may consider alternative therapies. If used, close monitoring of both mother and infant is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other NRTIs such as tenofovir. Compared with tenofovir, lamivudine generally has a lower risk of renal toxicity but may be less potent as a single agent, making it useful in combination regimens.

Lamivudina Normon tablets should be stored at ambient temperature, preferably below 25 °C, in a dry place. Keep the container tightly closed, protect from moisture and direct sunlight, and retain the original packaging until use.

The medication is taken orally as a tablet, usually with water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

Serious adverse events include severe lactic acidosis, hepatic steatosis (fatty liver disease) and hypersensitivity reactions that may involve rash, fever or organ involvement. Prompt medical evaluation is required if any of these symptoms develop.

Patients with known hypersensitivity to lamivudine or any component of the tablet should avoid the product. Those with severe liver disease or uncontrolled mitochondrial disorders should also be cautioned, and the decision to treat should be made by a qualified healthcare professional.